To address this, we pre-treated anti-AIM2 +SLE sera and the AIM2 IVTT product with DNase prior to combining them in the IP reaction, and found that SLE sera retained the ability to bind AIM2 following DNase treatment (Figure 1C–D). Here, AIM2 is linked to systemic lupus erythematosus.